See ratings and reviews when you sign up for an account.

A Single-center, Proof of Concept, Randomized, Controlled Parallel Group Clinical Trial of the Effects of Exenatide Versus a Long Acting Insulin Analog for 18 Months to Evaluate the Efficacy of Exenatide Therapy in Patients With Diabetic Peripheral Neuropathy and Type 2 Diabetes

This study is currently Recruiting

August 2011 By University of Michigan

First Recieved on March 3, 2009

Last Updated on August 4, 2011

Sponsor: University of Michigan
Collaborators: Amylin Pharmaceuticals, Inc.
Information provided by: University of Michigan
Identifier: NCT00855439


This study will look at whether or not the medication exenatide improves signs and symptoms of diabetic peripheral neuropathy in people with type 2 diabetes and mild to moderate diabetic peripheral neuropathy.

Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Ages Eligible for Study:18 Years
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No

Inclusion Criteria: - Type 2 diabetes treated with one or more oral agents - Persistent fasting glucose > 140 mg/dl or HbA1c > 7% - Stable and maximally effective doses of one or more oral agents for 3 months - Presence of diabetic peripheral neuropathy - Age between 18 and 70 years - No risk factors or other causes of neuropathy - Willingness and capacity to sign the Institutional Review Board approved consent form and cooperate with the medical procedures for study duration Exclusion Criteria: - Nursing mothers or pregnant women - A history of previous kidney, pancreas or cardiac transplantation - A past history of neuropathy (independent of diabetes) or with a disease known to be associated with neuropathy (e.g., hepatitis C, end stage renal disease, lupus) - Amputation of any part of either lower extremity for any reason or traumatic loss of any part of either lower extremity or congenital absence or severe deformity of lower extremity - HbA1c > 10% - Participation in an experimental medication trial within 3 months of starting the study. - Undergoing therapy for malignant disease other than basal- or squamous cell carcinoma - Requiring long-term glucocorticoid therapy - Inability or unwillingness to comply with the protocol


  • Investigator: Rodica Pop-Busui, MD, PhD - Principal Investigator - University of Michigan


  • The University of Michigan Health System

    Ann Arbor, Michigan 48109 United States

Conditions related to this trial:

Disclaimer: The list and ratings above are for informational purposes only, and is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. The goal of the information is to provide you with a comprehensive view of all available treatments, but should not be construed to indicate that use of any one treatment is safe, appropriate, or effective for you. Decisions about use of a new treatment, or about a change in your current treatment plan, should be in consultation with your doctor or other healthcare professional.